- Home
- TCBS vs RNTX Comparison
TCBS vs RNTX Comparison
Compare TCBS & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCBS
- RNTX
- Stock Information
- Founded
- TCBS 1934
- RNTX 2001
- Country
- TCBS United States
- RNTX United States
- Employees
- TCBS N/A
- RNTX N/A
- Industry
- TCBS Banks
- RNTX Biotechnology: Pharmaceutical Preparations
- Sector
- TCBS Finance
- RNTX Health Care
- Exchange
- TCBS Nasdaq
- RNTX Nasdaq
- Market Cap
- TCBS 48.8M
- RNTX 40.3M
- IPO Year
- TCBS N/A
- RNTX N/A
- Fundamental
- Price
- TCBS $16.21
- RNTX $1.54
- Analyst Decision
- TCBS
- RNTX
- Analyst Count
- TCBS 0
- RNTX 0
- Target Price
- TCBS N/A
- RNTX N/A
- AVG Volume (30 Days)
- TCBS 3.8K
- RNTX 33.8K
- Earning Date
- TCBS 08-12-2025
- RNTX 08-13-2025
- Dividend Yield
- TCBS 1.00%
- RNTX N/A
- EPS Growth
- TCBS N/A
- RNTX N/A
- EPS
- TCBS 0.68
- RNTX N/A
- Revenue
- TCBS $14,488,000.00
- RNTX N/A
- Revenue This Year
- TCBS N/A
- RNTX N/A
- Revenue Next Year
- TCBS N/A
- RNTX N/A
- P/E Ratio
- TCBS $23.59
- RNTX N/A
- Revenue Growth
- TCBS 54.08
- RNTX N/A
- 52 Week Low
- TCBS $13.52
- RNTX $1.33
- 52 Week High
- TCBS $17.50
- RNTX $4.40
- Technical
- Relative Strength Index (RSI)
- TCBS 58.70
- RNTX N/A
- Support Level
- TCBS $15.90
- RNTX N/A
- Resistance Level
- TCBS $16.15
- RNTX N/A
- Average True Range (ATR)
- TCBS 0.09
- RNTX 0.00
- MACD
- TCBS -0.00
- RNTX 0.00
- Stochastic Oscillator
- TCBS 87.14
- RNTX 0.00
About TCBS Texas Community Bancshares Inc.
Texas Community Bancshares Inc is a holding company. The company's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank of Dallas, in residential real estate loans and commercial real estate loans and, to a lesser extent, commercial loans, construction and land loans, and consumer and other loans. Its portfolio segments are real estate, agriculture, commercial, consumer and other.
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.